Clinical trials: Hereditary Haemochromatosis
Chronic Liver Disease
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.
- Trial name
- FALL (NCT05335603)
- Where
- Denmark
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Genetic Hemochromatosis
Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study
The purpose of this study is to describe bone status on patients with genetic hemochromatosis, at diagnostic time and his evolution under treatment.
- Trial name
- FEROS (NCT01556360)
- Where
- 6 sites in France
- Volunteers
- 100 people
- Sponsor
- Rennes University Hospital
Glomerulonephritis, Membranous, Neonatal Diseases and Abnormalities
Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Problems of compatibility between a mother and her child are frequent. The most well-known case can be illustrated by the fetomaternal blood group incompatibility (rhesus factor) which can induce severe anemia of the fetus.
- Conditions
- Glomerulonephritis, Membranous, Neonatal Diseases and Abnormalities, Hemochromatosis
- Trial name
- NCT00199628
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Limoges
Hereditary Hemochromatosis
Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients
Hereditary hemochromatosis (HH) is a genetic disorder of iron metabolism, resulting in excessive iron overload. Phlebotomy is currently the standard therapy.
- Trial name
- NCT01398644
- Testing
- Phlebotomy and erythrocytapheresis
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sanquin Research & Blood Bank Divisions
Hemochromatosis, Myelodysplastic Syndromes
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC.
- Trial name
- DefeHEMY (NCT01892644)
- Testing
- Deferasirox, Venesection
- Where
- Norway
- Volunteers
- healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Hemochromatosis
Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferrioxamine
- Trial name
- NCT00349453
- Testing
- Deferiprone (L1), Desferrioxamine
- Where
- 13 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Lipomed
Haemochromatosis
Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis
Patients in maintenance treatment for HFE hemochromatosis since at least one year will be included in a two year study period and randomized in two groups experimental and control group.
- Trial name
- Quali-SAT (NCT04779593)
- Testing
- Clinical examination, SF36 questionnaire, AIMS2_SF questionnaire
- Where
- 12 sites in France
- Volunteers
- 239 people
- Sponsor
- Rennes University Hospital
Dysmetabolic Iron Overload Syndrome, Genetic Hemochromatosis
Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.
Dysmetabolic iron overload syndrome and genetic hemochromatosis are frequent causes of iron overload. Polyphenols are efficient iron-chelators.
- Conditions
- Dysmetabolic Iron Overload Syndrome, Genetic Hemochromatosis, Iron Absorption, Polyphenols
- Trial name
- POLYFER (NCT03453918)
- Testing
- polyphenols
- Where
- France
- Volunteers
- 41 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hemochromatoses, Genetic
Transferrin Saturation and Asthenia in Hemochromatosis
Observational study.
- Trial name
- HEMOSAT (NCT03356548)
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Rennes University Hospital
Beta-thalassemia, Myelodysplastic Syndromes
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
The purpose of this study is to determine the effects of the oral iron chelator Deferasirox on liver iron content after one year of treatment in patients with iron overload from repeated blood transfusions.
- Conditions
- Beta-thalassemia, Myelodysplastic Syndromes, Fanconi Syndrome, Anemia, Diamond-Blackfan
- Trial name
- NCT00061763
- Testing
- Deferasirox
- Where
- 6 sites in United States
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals